German health care company Fresenius Kabi has announced the US launch of Arsenic Trioxide Injection – a generic version of Teva Pharmaceutical Industries’ leukemia drug Trisenox.
Arsenic Trioxide Injection, like its reference medicine, is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL). The indication is for APL patients, who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose condition is characterized by the presence of the translocation or PML/RAR-alpha gene expression.
Arsenic Trioxide Injection, which has been launch in 10mg per 10mL vial, is the first-to-market generic of Trisenox for the treatment of relapsed or refractory acute promyelocytic leukemia.
John Ducker – president and CEO of Fresenius Kabi USA, commenting on the US launch of Arsenic Trioxide Injection, said:
“With the introduction of Arsenic Trioxide Injection, Fresenius Kabi is pleased to continue to expand its broad oncology portfolio, providing patients and clinicians with access to affordable generic alternatives of vital medicines.
“We’re also pleased to bring back the 10 mg per 10 mL (1 mg per mL) presentation of Arsenic Trioxide Injection – now in a vial – to provide a familiar alternative to clinicians.”